JEROME LASTIMOSA: Open Payments
NPI 1588316798 · GLEN BURNIE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$424 in 14 payments from 7 companies in 2025. Trend: 2023 $0 · 2024 $272 · 2025 $424
Food & beverage: $424
| Company | Payments | Amount |
|---|---|---|
| Corcept Therapeutics | 5 | $126 |
| Dexcom, Inc. | 1 | $114 |
| Novo Nordisk Inc | 4 | $103 |
| ABBVIE INC. | 1 | $25 |
| Astellas Pharma US Inc | 1 | $21 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $19 |
| PFIZER INC. | 1 | $16 |
Products named: Korlym, DEXCOM G7 GSS (161), Wegovy, UBRELVY, Veozah, XIFAXAN, PAXLOVID.
Industry payments across MD — which companies pay providers there.
